Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Edaravone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Edaravone. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-003900-42 Sponsor Protocol Number: MT-1186-A04 Start Date*: 2022-07-15
    Sponsor Name:Mitsubishi Tanabe Pharma America, Inc. (MTPA)
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following S...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004256-11 Sponsor Protocol Number: MT-1186-A02 Start Date*: 2021-05-11
    Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
    Full Title: A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000376-38 Sponsor Protocol Number: MT-1186-A03 Start Date*: 2021-03-22
    Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc.
    Full Title: A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000586-37 Sponsor Protocol Number: CY5022 Start Date*: 2018-09-13
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Scler...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003676-31 Sponsor Protocol Number: ROCK-ALS Start Date*: 2019-12-31
    Sponsor Name:Georg-August-Universität Göttingen
    Full Title: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002108-41 Sponsor Protocol Number: MT-1186-A01 Start Date*: 2020-05-06
    Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc.
    Full Title: A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000207-36 Sponsor Protocol Number: 275AS101 Start Date*: 2020-11-18
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 ...
    Medical condition: ALS and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10052653 Amyotrophic lateral sclerosis gene carrier PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004098-33 Sponsor Protocol Number: 233AS101 Start Date*: 2016-06-29
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide D...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077024 Familial amyotrophic lateral sclerosis PT
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004619-30 Sponsor Protocol Number: ALXN1210-ALS-308 Start Date*: 2020-09-14
    Sponsor Name:Alexion Pharmaceuticals
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotroph...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS), motor neuron disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004156-42 Sponsor Protocol Number: ACT16970 Start Date*: 2022-04-12
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an ...
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Ongoing) NL (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FR (Temporarily Halted) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003225-41 Sponsor Protocol Number: 233AS102 Start Date*: 2017-04-10
    Sponsor Name:Biogen Idec Research Limited
    Full Title: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sc...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077024 Familial amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) DK (Ongoing) PL (Completed) ES (Prematurely Ended) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000250-26 Sponsor Protocol Number: A35-004 Start Date*: 2021-10-27
    Sponsor Name:Amylyx Pharmaceuticals Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic L...
    Medical condition: ALS (amyotrophic lateral sclerosis)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Ongoing) SE (Ongoing) NL (Ongoing) ES (Ongoing) PT (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003164-27 Sponsor Protocol Number: TW001-AD-C2.01 Start Date*: 2022-06-28
    Sponsor Name:Treeway TW001AD B.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients
    Medical condition: Alzheimer´s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003397-17 Sponsor Protocol Number: MCI-186-E04 Start Date*: 2009-01-23
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of ...
    Medical condition: Acute ischemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002754-36 Sponsor Protocol Number: 3119002 Start Date*: 2018-05-08
    Sponsor Name:Orion Corporation
    Full Title: Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS
    Medical condition: Amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) BE (Completed) FI (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005611-31 Sponsor Protocol Number: CORT113176-652 Start Date*: 2022-09-07
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis (DAZALS)
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) ES (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005193-94 Sponsor Protocol Number: WVE-004-001 Start Date*: 2021-12-20
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Front...
    Medical condition: Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IE (Completed) SE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003376-40 Sponsor Protocol Number: FAB122-CT-2001 Start Date*: 2021-08-10
    Sponsor Name:Ferrer Internacional, S.A.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) NL (Completed) DE (Completed) ES (Ongoing) PL (Completed) IT (Ongoing) SE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003050-32 Sponsor Protocol Number: FAB122-CT-2201 Start Date*: 2023-02-21
    Sponsor Name:Ferrer Internacional S.A.
    Full Title: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) PL (Prematurely Ended) DE (Completed) SE (Completed) ES (Ongoing) PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005971-11 Sponsor Protocol Number: AP101-02 Start Date*: 2021-10-20
    Sponsor Name:AL-S Pharma, AG
    Full Title: A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA